Xenetic reports FY2021 net loss of $5.6M; royalty revenue up 166% to $1.2M

Xenetic Biosciences, Inc.

Net loss for FY2021 was approx $5.6M; R&D expenses rose to $3.2M (vs $1.7M in 2020) on XCART investment.
Cash at year-end $18.2M; working capital $17.3M, up from $11.4M in 2020.
Royalty payments from PolyXen platform totaled $1.2M, up 166% YoY, from Takeda sublicensee product launches.
XCART program advancing toward IND-enabling studies; U.S. patent for co-administration with personalized vaccine issued.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.